<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677844</url>
  </required_header>
  <id_info>
    <org_study_id>16080</org_study_id>
    <secondary_id>I3Y-MC-JPCA</secondary_id>
    <nct_id>NCT02677844</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib in Healthy Participants</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:

        -  The effect of single increasing doses of the study drug, abemaciclib, on healthy
           participants.

        -  The relationship between the amount of abemaciclib and the electrical tracing of the
           heart rhythm when abemaciclib is given.

        -  How much abemaciclib is found in the bloodstream and how long the body takes to get rid
           of it.

      Information about any side effects that occur will be collected. The study will enroll two
      groups (cohorts) of participants. Each group will complete 4 study periods. This study is
      expected to last about 3 months. Screening may occur up to 28 days prior to enrollment. All
      participants will undergo a follow-up assessment approximately 21 days after administration
      of their final dose of study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time-Matched Difference in Fridericia's corrected QT interval (QTcF) Between Abemaciclib compared to Placebo</measure>
    <time_frame>Day 1: Two hours post dose through 120 hours post dose in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Abemaciclib</measure>
    <time_frame>Day 1: Two hours post dose through 120 hours post dose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve (AUC) of Abemaciclib</measure>
    <time_frame>Day 1: Two hours post dose through 120 hours post dose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Loperamide</measure>
    <time_frame>Day 1: Two hours post dose through 120 hours post dose in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of Loperamide</measure>
    <time_frame>Day 1: Two hours post dose through 120 hours post dose in each period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo on Day 1 of 1 study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loperamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2, only. Loperamide given orally once in 1 of 4 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loperamide + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2, only. Loperamide coadministered with abemaciclib given orally once in up to 1 of 4 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loperamide + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2, only. Loperamide coadministered with placebo given orally once in up to 1 of 4 study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib</arm_group_label>
    <arm_group_label>Loperamide + Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Loperamide + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Loperamide</arm_group_label>
    <arm_group_label>Loperamide + Abemaciclib</arm_group_label>
    <arm_group_label>Loperamide + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

               -  Male participants will be sterile

               -  Female participants must not be of childbearing potential

        Exclusion Criteria:

          -  Have known allergies to abemaciclib, related compounds, or any components of the
             formulation

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) including a Fridericia's
             corrected QT interval (QTcF) greater than 450 milliseconds (ms) (males) or greater
             than 470 ms (females)

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs

          -  Have a gastrointestinal disorder causing clinically significant symptoms such as
             nausea, vomiting, and diarrhea, or malabsorption syndromes, or constipation

        Additional Exclusion Criterion for Participants Enrolled in Cohort 2:

          -  Have a known hypersensitivity to loperamide hydrochloride or to any of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

